Ormutivimab
Based on 1 Customer Validation
Ormutivimab (rhRIG) is a recombinant human monoclonal antibody, targeting rabies virus. Ormutivimab neutralizes a variety of rabies virus strains. Ormutivimab exhibits potent potency against rabies post-exposure prophylaxis (PEP) model.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 95%
- CAS No.: 2449086-91-1
- Masse moléculaire:146.1 kDa
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
Human IgG1 lambda2
Virus
RABVG
Ormutivimab (20 IU/kg, 100 IU/kg; i.m.; single dose) protects challenged Kunming mice against various rabies virus[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Balb/c mice challenge model with rabies virus[1]
-
Dosage:20 IU/kg, 100 IU/kg
-
Administration:Intramuscular injection; single dose after 4 hr after infection
-
Result:Protected mice from rabies CVS-24 and GZ-1 isolates at a comparable rate (90%) to that of HRIG, human antirabies immune globulin.
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG1 lambda2
ELISA, FACS, Functional assay
Chemical Information
-
CAS No. 2449086-91-1
-
Appearance Liquid
-
Masse moléculaire 146.1 kDa
-
Color Colorless to light yellow
-
SMILES
[Ormutivimab]
-
Synonyms
NM57; rhRIG
-
Livraison
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
-
Fiche technique (259 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Références
[1]. Zhai LL, et al. Efficacy of ormutivimab, a novel recombinant human anti-rabies monoclonal antibody, in post-exposure prophylaxis animal models. Travel Med Infect Dis. 2022 Mar-Apr;46:102267. [Content Brief]
[2]. Zhang J, et al. Population Pharmacodynamic Analyses of Human Anti-Rabies Virus Monoclonal Antibody (Ormutivimab) in Healthy Adult Subjects. Vaccines (Basel). 2022 Jul 29;10(8):1218. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz